Abstract
BACKGROUND: Thyroid nodules are frequently encountered in clinical practice, with their detection increasing due to advancements in imaging modalities. While most nodules are benign, distinguishing papillary thyroid carcinoma (PTC) from benign entities such as multinodular goiter (MNG) remains a diagnostic challenge. Fine-needle aspiration (FNA) and sonography are standard tools, but their limitations highlight the need for supplementary approaches. This study evaluates the use of machine learning (ML) models to classify PTC versus MNG using routine preoperative clinical, laboratory, and cytological data before performing surgery and Pathology results. METHODS: This retrospective multicenter study included 971 patients who underwent total thyroidectomy between 2020 and 2024. The dataset incorporated demographic data, preoperative sonographic findings, hematologic and thyroid function tests, and FNA cytology results. Five supervised ML algorithms—Logistic Regression, Random Forest, XGBoost, Support Vector Machine (SVM), and K-Nearest Neighbor (KNN)—were trained and validated. Model performance was assessed using accuracy, precision, recall, F1-score, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC). RESULTS: The XGBoost model achieved the best performance, with an accuracy of 84.4%, precision of 85.3%, and an AUC-ROC of 0.881. It also demonstrated high sensitivity (0.714) and specificity (0.944). Random Forest also performed well (accuracy: 81.2%, AUC-ROC: 0.919). Logistic Regression, SVM, and KNN underperformed in comparison. Feature importance analysis revealed that the FNA result, nodule size, and TSH were the most influential predictors. CONCLUSION: Machine learning models, particularly XGBoost and Random Forest, show promise in accurately distinguishing between MNG and PTC using routine clinical data. Their integration into preoperative assessment may enhance diagnostic precision, reduce unnecessary procedures, and support personalized surgical decision-making. Further validation in diverse, multicenter cohorts is warranted to confirm generalizability and clinical utility. CLINICAL TRIAL NUMBER: Not applicable.